Další formáty:
BibTeX
LaTeX
RIS
@article{2361031,
author = {Grega, Dominik and Kolář, Jozef},
article_location = {AMSTERDAM},
article_number = {March},
doi = {http://dx.doi.org/10.1016/j.vhri.2023.10.001},
keywords = {direct costs; elasticity factor; friction period; indirect costs; loss of productivity.},
language = {eng},
issn = {2212-1099},
journal = {Value in Health Regional Issues},
title = {The Economic Burden of Biological Drugs in Rheumatoid Arthritis Treatment},
url = {https://www.valuehealthregionalissues.com/article/S2212-1099(23)00109-7/fulltext},
volume = {40},
year = {2024}
}
TY - JOUR
ID - 2361031
AU - Grega, Dominik - Kolář, Jozef
PY - 2024
TI - The Economic Burden of Biological Drugs in Rheumatoid Arthritis Treatment
JF - Value in Health Regional Issues
VL - 40
IS - March
SP - 13-18
EP - 13-18
PB - Elsevier
SN - 22121099
KW - direct costs
KW - elasticity factor
KW - friction period
KW - indirect costs
KW - loss of productivity.
UR - https://www.valuehealthregionalissues.com/article/S2212-1099(23)00109-7/fulltext
N2 - Objectives: This article aimed to count and compare treatment's direct (only biological drugs) and indirect (loss of productivity) costs in patients with rheumatoid arthritis from 2019 to 2021.Methods: The friction cost approach was used to establish indirect costs. Elasticity factor values and friction period for the Slovak Republic from 2019 to 2021 were determined. Direct drug costs were calculated based on average prices from 2019 to 2021 and the number of dispensed medication packages.Results: The average productivity loss reached euro2984.54 in 2019, euro3338.46 in 2020, and euro3154.01 in 2021. Total indirect costs include productivity loss and sick pay, and from 2019 to 2021 came the values of euro8.4 million, euro10.1 million, and euro8.1 million, respectively. Conclusions: Indirect costs were almost 2.5 to 3 times lower than the biological and targeted treatment costs.
ER -
GREGA, Dominik a Jozef KOLÁŘ. The Economic Burden of Biological Drugs in Rheumatoid Arthritis Treatment. \textit{Value in Health Regional Issues}. AMSTERDAM: Elsevier, 2024, roč.~40, March, s.~13-18. ISSN~2212-1099. Dostupné z: https://dx.doi.org/10.1016/j.vhri.2023.10.001.
|
